LOTEMAX SM Drug Patent Profile
✉ Email this page to a colleague
When do Lotemax Sm patents expire, and what generic alternatives are available?
Lotemax Sm is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-seven patent family members in thirteen countries.
The generic ingredient in LOTEMAX SM is loteprednol etabonate. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lotemax Sm
A generic version of LOTEMAX SM was approved as loteprednol etabonate by SENTISS on April 17th, 2019.
Summary for LOTEMAX SM
| International Patents: | 27 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 22 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LOTEMAX SM |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LOTEMAX SM |
| What excipients (inactive ingredients) are in LOTEMAX SM? | LOTEMAX SM excipients list |
| DailyMed Link: | LOTEMAX SM at DailyMed |
Recent Clinical Trials for LOTEMAX SM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Thomas Chester, OD | Phase 4 |
| Illinois College of Optometry | Early Phase 1 |
| Shiraz University of Medical Sciences | Phase 4 |
Pharmacology for LOTEMAX SM
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for LOTEMAX SM
Paragraph IV (Patent) Challenges for LOTEMAX SM
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| LOTEMAX SM | Ophthalmic Gel | loteprednol etabonate | 0.38% | 208219 | 1 | 2022-11-14 |
US Patents and Regulatory Information for LOTEMAX SM
LOTEMAX SM is protected by two US patents.
Patents protecting LOTEMAX SM
Ophthalmic suspension composition
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | LOTEMAX SM | loteprednol etabonate | GEL;OPHTHALMIC | 208219-001 | Feb 22, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Bausch And Lomb Inc | LOTEMAX SM | loteprednol etabonate | GEL;OPHTHALMIC | 208219-001 | Feb 22, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LOTEMAX SM
See the table below for patents covering LOTEMAX SM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Mexico | 2017009699 | COMPOSICION DE SUSPENSION OFTALMICA. (OPHTHALMIC SUSPENSION COMPOSITION.) | ⤷ Try a Trial |
| Australia | 2016211745 | Ophthalmic suspension composition | ⤷ Try a Trial |
| European Patent Office | 3470059 | COMPOSITION DE SUSPENSION OPHTALMIQUE (OPHTHALMIC SUSPENSION COMPOSITION) | ⤷ Try a Trial |
| Spain | 2787039 | ⤷ Try a Trial | |
| European Patent Office | 3721868 | COMPOSITION DE SUSPENSION OPHTALMIQUE (OPHTHALMIC SUSPENSION COMPOSITION) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
